At Worldwide, we know rare liver disease programs depend on precise operational execution. Our dedicated liver team brings feasibility intelligence, targeted recruitment, and deep site and KOL relationships to help deliver complex cholestatic and rare liver studies with confidence.
We’ll connect you with the right cholestatic or rare liver disease development team.
Why Cholestatic & Rare Liver Programs Demand Specialized Support
Rare liver disease studies face challenges beyond protocol design: limited, dispersed patient populations, heterogeneous presentation, and changing endpoint expectations. Worldwide addresses these with specialist hepatology center relationships, adaptive trial designs, and expertise across biochemical, imaging, histologic, and patient-reported endpoints. Our scientific insight into rare-disease operational strategies helps sponsors maintain endpoint confidence.

Partnership & Approach
Successful liver disease development requires more than therapeutic expertise. It requires continuity, accountability, and a team that understands the operations for complex studies. At Worldwide, sponsors work directly with liver-focused medical directors, scientific leaders, and experienced project managers, all engaged throughout the program. Our team’s combined 150+ years of experience provides consistent scientific guidance, proactive risk management, and specialized oversight from study design through final reporting.
Worldwide’s cholestatic and rare liver disease programs are supported by a broader rare disease infrastructure spanning more than 90 countries, 29,500+ enrolled patients, 210+ projects, 100+ indications, and 6,100+ site activations. This experience provides sponsors with proven strategies for identifying specialist sites, engaging difficult-to-reach patient populations and executing complex global studies in low-prevalence diseases, while maintaining scientific rigor and operational consistency across regions.
Patients
Sites
Countries
A global PSC Phase II program that met its enrollment milestone 4.5 months ahead of schedule supported positive topline results for the sponsor.

Subjects
Sites
Two global Phase II programs in acute liver failure, delivered in a population where timing and site readiness decide whether a patient can be enrolled.

Routinely Partnered Liver Sites
Including specialist cholestatic and rare liver centers across 30+ countries, with long-standing KOL relationships across EASL, AASLD and patient advocacy communities.

Why Worldwide for Cholestatic Liver Disease Trials
Rare liver disease trials require access to concentrated patient populations and established referral networks. Worldwide maintains relationships with dedicated cholestatic liver centers, leading hepatologists, gastroenterologists, and KOLs across major research markets. These long-standing collaborations support informed feasibility, stronger site engagement, and faster access to qualified patients.
Rare cholestatic liver programs require regulatory strategies tailored to small populations, limited natural history data, and shifting endpoint expectations. Worldwide supports early engagement with FDA, EMA, MHRA, and PMDA, as well as orphan drug designation, expedited pathways, and pediatric development planning through PIPs and iPSPs. Liver experts also oversee hepatic safety monitoring and DILI causality assessment, helping sponsors navigate regulatory complexity while maintaining patient safety and development momentum.
Rare cholestatic liver programs require study designs that maximize insight from limited patient populations. Worldwide applies adaptive trial methodologies that optimize decision-making and enrollment while aligning with regulatory expectations. Combined with cross-border enrollment strategies, specialist site networks, and region-specific operational planning, this approach helps expand patient access, maintain enrollment momentum, and protect endpoint integrity.
Frequently Asked Questions
We’ve answered some of the most common questions we receive about cholestatic and rare liver disease development. If you need additional insight, our dedicated liver team is ready to help.
Worldwide has supported clinical development programs across PBC, PSC, autoimmune hepatitis, decompensated liver disease, alcoholic hepatitis, and acute liver failure, including a global Phase II PSC study that enrolled 110+ patients across 65+ sites in 11 countries and achieved its enrollment milestone 4.5 months ahead of schedule. Worldwide has also delivered two global Phase II acute liver failure studies involving 314 participants across 75 sites.
Worldwide manages liver biopsy collection, processing, and interpretation within our dedicated liver team rather than through a fragmented outsourcing model, coordinated under the same scientific leadership for integrated oversight. Centralized biopsy management, AI-assisted histopathology review through our preferred relationship with PathAI, and standardized pathology workflows help promote consistent histologic assessment across sites and regions.
Worldwide works with an established, long-standing relationship with global network of hepatology and gastroenterology investigators, KOLs, and patient advocacy groups experienced in cholestatic, rare, and advanced liver disease research. Including EASL and AASLD, these relationships are developed and maintained over time, allowing sponsors to gain early access to scientific insight, informed feasibility assessments, specialized sites, and experienced investigators who can help accelerate study planning and execution.
Rare liver studies often combine invasive procedures with symptom-driven endpoints, creating significant burden for patients and families. Worldwide addresses this through patient-centric study design informed with patient advocacy perspectives, standardized assessment training and oversight, and operational strategies that reduce unnecessary travel and site visits. We support caregivers for pediatric and adolescent populations, and leverage cross-border enrollment and referral networks to bring studies closer to home.
Worldwide supports rare liver disease programs with integrated imaging, biomarker, and pathology expertise designed to strengthen endpoint quality and consistency across global studies. Our experience includes non-invasive imaging modalities such as MRI-PDFF, MRE, VCTE/Fibroscan®, and ultrasound elastography, alongside blood-based biomarker strategies incorporating ELF, PRO-C3, NIS4+, FIB-4, APRI, and FibroSURE®/FibroTest. Preferred partnerships help ensure standardized image acquisition, centralized interpretation, and AI-assisted pathology review across a global site network.